OKYO Pharma to Present at OIS XV in San Diego London and New York, NY

Pharma to Present at OIS XV in San Diego

and New York, NY, November 18, 2025. OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which

is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related

pain but without an FDA-approved therapy, announced that Gary S. Jacob, Ph.D., Chief Executive Officer, will present at the Ophthalmology

Innovation Summit (OIS) XV. The presentation is scheduled for Saturday, November 22, 2025, from 8:30-9:30 AM PT, as part of the "Anterior

Innovation Showcase" session.

XV, taking place November 21-22, 2025, at the San Diego Marriott Marquis & Marina in San Diego, California, is a premier annual event

organized by Ophthalmology Innovation Source. The summit brings together leading innovators, investors, executives, and clinicians in

the eye care field to foster unparalleled networking and deliver cutting-edge insights into ophthalmic innovation. With a focus on anterior

and posterior segment advancements, the conference features panel discussions, company showcases, and one-on-one partnering meetings,

attracting global stakeholders committed to advancing treatments for vision-threatening conditions.

Jacob's presentation will highlight OKYO's lead investigational drug candidate, urcosimod, a lipidated peptide designed to

treat NCP, a major unmet medical need. Building on recent positive top-line results from a Phase 2 trial in NCP-announced earlier

this year-OKYO is advancing toward a 120-patient multi-center clinical trial, underscoring the company's commitment to addressing

unmet needs in this underserved market. Urcosimod demonstrated promising anti-inflammatory and pain-relieving effects in a previous Phase

are thrilled to showcase our progress with urcosimod at OIS XV, a cornerstone event for ophthalmic innovation," said Gary S. Jacob,

Ph.D., Chief Executive Officer of OKYO Pharma. "The recent Phase 2 data on NCP patients, reinforces urcosimod's potential

to transform the treatment landscape for neuropathic corneal pain that affects sufferers worldwide with no FDA-approved options. The

OIS XV meeting will allow us to engage with key opinion leaders and potential partners to accelerate our development of urcosimod for

patients who desperately need effective therapies."

Neuropathic Corneal Pain (NCP)

is a condition that causes severe eye pain and sensitivity of the eyes. The exact cause of NCP is unknown but is thought to result from

nerve damage to corneal nerves combined with inflammation. NCP, which can exhibit as a severe, chronic, debilitating condition in patients

suffering from a host of ophthalmic conditions, is presently treated, with limited success, by various topical and systemic treatments

in an off-label fashion.

Urcosimod (formerly called OK-101)

is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of

the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed

using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. Urcosimod has

been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain,

respectively. Urcosimod showed clear statistical significance in multiple endpoints in a 240-patient Phase 2, multi-center, double-masked,

placebo-controlled trial to treat dry eye disease, and is presently being evaluated in a just-completed

randomized, placebo-controlled, double-masked Phase 2 trial involving 17 neuropathic corneal pain patients.

Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic

corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery

and development of novel molecules to treat neuropathic corneal pain and ocular diseases. In addition to the completed Phase 2 trial

of urcosimod to treat dry eye disease patients, OKYO is also currently evaluating urcosimod to treat neuropathic corneal pain patients,

and recently completed a Phase 2 trial.

further information, please visit www.okyopharma.com.